Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Qiaofei Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7148-2850; OpenAlex author ID A5010228018. Sources: OpenAlex.

Their work

Papers
31 (first author 11, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 8 papers · 2021: 5 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers

Papers 31

  1. NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Co-author DOI 10.1016/j.celrep.2024.115226↗
  2. Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Last author DOI 10.1136/jitc-2025-012163↗
  3. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Co-author DOI 10.1016/j.canlet.2024.217280↗
  4. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Last author DOI 10.1016/j.canlet.2024.217289↗
  5. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Co-author DOI 10.1186/s12943-024-02184-8↗
  6. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological c… Co-author DOI 10.1007/s00259-022-06100-4↗
  7. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… Co-author DOI 10.1007/s00259-023-06297-y↗
  8. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  9. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  10. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.968610↗
  11. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-020-02203-3↗
  12. Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.omto.2021.08.012↗
  13. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. First author DOI 10.1186/s12935-021-01824-z↗
  14. Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12935-021-02037-0↗
  15. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fimmu.2021.774435↗
  16. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  17. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Co-author DOI 10.1038/s41598-020-61487-0↗
  18. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.15856↗
  19. Identification of prognosis-related genes and construction of multi-regulatory networks in pancreatic cancer microenvironment by bioinformatics analysis. First author DOI 10.1186/s12935-020-01426-1↗
  20. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. First author DOI 10.3389/fcell.2020.607209↗
  21. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. First author DOI 10.7150/jca.37445↗
  22. High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.39800↗
  23. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. First author DOI 10.7150/jca.40517↗
  24. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.02.043↗
  25. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. First author DOI 10.1038/s41419-019-2065-4↗
  26. Fibroblast activation protein α-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylatio… First author DOI 10.21037/atm.2019.09.164↗
  27. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. Co-author DOI 10.1016/j.cyto.2015.12.003↗
  28. Chemotherapy and tumor microenvironment of pancreatic cancer. Co-author DOI 10.1186/s12935-017-0437-3↗
  29. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative re… Co-author DOI 10.1007/s00262-016-1853-2↗
  30. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by … Co-author DOI 10.1186/s13046-016-0304-4↗
  31. Changes in the Expression of Glucose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models. First author DOI 10.3881/j.issn.1000-503x.2015.03.002↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 17 shared papers, 2015–2025 · strength 2.23
  2. Yalu Zhang · 7 shared papers, 2021–2025 · strength 1.28
  3. Yupei Zhao · 11 shared papers, 2016–2024 · strength 1.23
  4. Quan Liao · 7 shared papers, 2019–2024 · strength 0.98
  5. Sen Yang · 5 shared papers, 2020–2025 · strength 0.98
  6. Ronghua Zhang · 6 shared papers, 2019–2025 · strength 0.92
  7. Mengyi Wang · 9 shared papers, 2015–2022 · strength 0.91
  8. Ming Cui · 6 shared papers, 2020–2024 · strength 0.85
  9. Junchao Guo · 5 shared papers, 2019–2025 · strength 0.76
  10. Jorg H. Kleeff · 4 shared papers, 2020–2025 · strength 0.75
  11. Tong Li · 5 shared papers, 2020–2024 · strength 0.71
  12. Taiping Zhang · 5 shared papers, 2019–2023 · strength 0.64
  13. Junyi Gao · 4 shared papers, 2020–2024 · strength 0.62
  14. Zhiyong Liang · 4 shared papers, 2019–2025 · strength 0.60
  15. Gary Guishan Xiao · 3 shared papers, 2020–2025 · strength 0.54
  16. Menghua Dai · 4 shared papers, 2020–2023 · strength 0.49
  17. Wenchao Xu · 2 shared papers, 2024–2025 · strength 0.45
  18. Jianzhou Liu · 2 shared papers, 2024–2025 · strength 0.45
  19. Jingkai Liu · 3 shared papers, 2020–2021 · strength 0.44
  20. Huaijin Zheng · 2 shared papers, 2024–2025 · strength 0.44
  21. Lei You · 4 shared papers, 2019–2020 · strength 0.43
  22. Xiang Zhang · 3 shared papers, 2020–2021 · strength 0.42
  23. Junya Peng · 3 shared papers, 2019–2024 · strength 0.39
  24. Li Zhou · 3 shared papers, 2017–2024 · strength 0.36
  25. Zhixin Hao · 2 shared papers, 2023 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.